Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.

ABSTRACT:

Context

Treatment of advanced and recurrent endometrial cancer (EC) is still an unmet need for oncologists and gynecologic oncologists. The Cancer Genome Atlas Research Network (TCGA) recently provided a new genomic classification, dividing EC in four subgroups. Two types of EC, the polymerase epsilon (POLE)-ultra-mutated and the microsatellite instability-hyper-mutated (MSI-H), are characterized by a high mutation rate providing the rationale for a potential activity of checkpoint inhibitors.

Materials and methods

We analyzed all available evidence supporting the role of tumor microenvironment (TME) in EC development and the therapeutic implications offered by immune checkpoint inhibitors in this setting. We performed a review on Pubmed with Mesh keywords 'endometrial cance

SUBMITTER: Mittica G 

PROVIDER: S-EPMC5685772 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature